Latest Articles

Publication Date
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer OncLive

Published: Oct. 15, 2025, 5:46 p.m.
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer - OncLive

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer OncLive

Published: Oct. 15, 2025, 12:10 p.m.
Pregnancy and obstetric-neonatal outcomes of patients with thin endometrium using three different endometrial preparation protocols in frozen embryo transfer cycles: a historical cohort of 2671 patients - BioMed Central

Pregnancy and obstetric-neonatal outcomes of patients with thin endometrium using three different endometrial preparation protocols in frozen embryo transfer cycles: a historical cohort of 2671 patients BioMed Central

Published: Oct. 15, 2025, 9:49 a.m.
Multidisciplinary Management of Intracardiac Tumor Thrombus in Low-Grade Endometrial Stromal Sarcoma: Case Report and Literature Review - Frontiers

Multidisciplinary Management of Intracardiac Tumor Thrombus in Low-Grade Endometrial Stromal Sarcoma: Case Report and Literature Review Frontiers

Published: Oct. 15, 2025, 9:11 a.m.
Endometrial Cancer Treatment Market Forecast to Reach USD 53.7 Billion by 2035, Driven by Innovation and Expanding Access to Care – FMIBlog - FMIBlog

Endometrial Cancer Treatment Market Forecast to Reach USD 53.7 Billion by 2035, Driven by Innovation and Expanding Access to Care – FMIBlog FMIBlog

Published: Oct. 15, 2025, 6:44 a.m.
Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer geneonline.com

Published: Oct. 14, 2025, 6:39 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.
Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer - Nature

Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer Nature

Published: Oct. 14, 2025, 4:47 p.m.
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials - BMC Cancer

Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials BMC Cancer

Published: Oct. 14, 2025, 2:41 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!